Table 4.
Order and Patient Factors by Potential DDI Across Drug Interaction Databasesa
| Order Factors |
Patient Factors |
||||||
|---|---|---|---|---|---|---|---|
| DDI | Drug A/Drug B | Timing | Dose | Route | Condition | Observation | Medication |
| 1 | Amphetamine & Derivatives/MAOIs | 3/3 | |||||
| 2 | Atazanavir/PPIs | 3/3 | 3/3 | 2/3 | |||
| 3 | Febuxostat/Azathioprine & Mercaptopurine | 2/3 | |||||
| 4 | SSRIs/MAOIs | 3/3 | 1/3 | 1/3 | 2/3 | ||
| 5 | Irinotecan/Strong CYP3A4 inhibitors | 3/3 | 1/3 | ||||
| 6 | Narcotic Analgesics/MAOIs | 3/3 | 1/3 | 2/3 | |||
| 7 | Tricyclic Antidepressants/MAOIs | 3/3 | 1/3 | 1/3 | 3/3 | ||
| 8 | High-risk QT Prolonging Agents | 1/3 | 1/3 | 3/3 | 1/3 | 1/3 | |
| 9 | Ramelteon/Strong CYP1A2 Inhibitors | 1/3 | |||||
| 10 | Strong CYP3A4 Inducers/ protease inhibitors | 1/3 | 3/3 | ||||
| 11 | HMG Co-A Reductase Inhibitors/CYP3A4 and protease inhibitors | 2/3 | 2/3 | ||||
| 12 | CYP3A4 and protease inhibitors/ergot alkaloidsb | ||||||
| 13 | Tizanidine/CYP1A2 inhibitors | 1/3 | |||||
| 14 | Tranylcypromine/procarbazine | 2/2 | |||||
| 15 | Triptans/MAOIs | 2/2 | 1/2 | 1/2 | |||
| Total instances of agreement | 10 | 9 | 3 | 2 | 1 | 8 |
Abbreviations: MAOI, monoamine oxidase inhibitor; PPI, proton pump inhibitor; SSRI, selective serotonin reuptake inhibitor; CYP3A4, cytochrome P450 isozyme 3A4; CYP1A2, cytochrome P450 isozyme 1A2.
aData are fraction of evaluated references in agreement (eg, 2/3 indicates a factor was found in 2 of 3 references).
bNo factors identified.